Prediction of response to erythropoietin treatment in chronic anemia of cancer.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v84.4.1056.1056PMID 7741835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors.

  1993cited by this paper
• Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen

  1993cited by this paper
• Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.

  1993cited by this paper
• The hepatic acute-phase proteins α1-antitrypsin and α2-macroglobulin inhibit binding of transferrin to its receptor

  1993cited by this paper
• Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

  1993cited by this paper
• The hepatic acute-phase proteins alpha 1-antitrypsin and alpha 2-macroglobulin inhibit binding of transferrin to its receptor.

  1993cited by this paper
• Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma

  1993cited by this paper
• Inhibition of human erythroid colony‐forming units by interleukin‐1 is mediated by gamma interferon

  1992cited by this paper
• Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

  1992cited by this paper
• Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease

  1992cited by this paper
• Development and validation of prognostic models in metastatic breast cancer: a GOCS study.

  1992cited by this paper
• The therapeutic role of recombinant erythropoietin in anemic patients with intact endogenous production of erythropoietin.

  1992cited by this paper
• Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis

  1992cited by this paper
• Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.

  1992cited by this paper
• The application of recombinant erythropoietin in anemic patients with cancer.

  1992cited by this paper
• Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.

  1992cited by this paper
• Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production

  1992cited by this paper
• Progress in understanding the pathogenesis of the anemia of chronic disease.

  1992cited by this paper
• Association between the activation of macrophages, changes of iron metabolism and the degree of anaemia in patients with malignant disorders

  1992cited by this paper
• Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer.

  1992cited by this paper
• Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.

  1992cited by this paper
• [Anemia in chronic disorders].

  1991cited by this paper
• Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma

  1991cited by this paper
• Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin.

  1991cited by this paper
• Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.

  1991cited by this paper
• Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

  1991cited by this paper
• High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.

  1991cited by this paper
• Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events.

  1991cited by this paper
• Erythropoietin treatment of anemia associated with multiple myeloma.

  1990cited by this paper
• Decreased erythropoietin response in patients with the anemia of cancer.

  1990cited by this paper
• Correlation between neopterin, interferon‐gamma and haemoglobin in patients with haematological disorders

  1990cited by this paper
• Recombinant human erythropoietin for patients with AIDS treated with zidovudine.

  1990cited by this paper
• Anaemia of chronic disease: diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients.

  1990cited by this paper
• Serum transferrin receptor: a quantitative measure of tissue iron deficiency.

  1990cited by this paper
• In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).

  1990cited by this paper
• Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor.

  1990cited by this paper
• Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice.

  1989cited by this paper
• Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells.

  1989cited by this paper
• Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application.

  1989cited by this paper
• Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.

  1989cited by this paper
• Neopterin as a marker for activated cell-mediated immunity: application in HIV infection.

  1988cited by this paper
• Biological changes in serum antiproteases as related to tumor progression.

  1988cited by this paper
• Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro.

  1988cited by this paper
• Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells.

  1987cited by this paper
• Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.

  1986cited by this paper
• The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.

  1986cited by this paper
• Role of the reticuloendothelial system in the anaemia of rheumatoid arthritis. A study using the 59Fe-labelled dextran model.

  1974cited by this paper

• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Erythroferrone in Anemic Rats with Chronic Kidney Disease and Chemotherapy-Induced Anemia: An Early Biomarker for Hemoglobin Response and rHuEPO Hyporesponsiveness

  2024cites this paper
• [Anemia of chronic diseases: current state of the problem and perspectives].

  2023cites this paper
• Drug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran

  2023cites this paper
• Molecular Aspects and Treatment of Iron Deficiency in the Elderly

  2020cites this paper
• Anemia of cancer in a spontaneously breast cancer developing mouse model

  2019cites this paper
• Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia

  2018cites this paper
• Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.

  2016cites this paper
• ANEMIA OF CHRONIC DISEASE

  2015cites this paper
• Beyond soluble transferrin receptor: old challenges and new horizons.

  2015cites this paper
• Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma

  2015cites this paper
• The Clinical Value of Erythropoietin in Patients with Cancer

  2012cites this paper
• Nanoparticles Mediated Targeted Drug DeliverySystem of Some Antineoplastic Agents for theTreatment of Breast Cancer.

  2011cites this paper
• Erythropoietin for oncology supportive care.

  2011cites this paper
• High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients.

  2010cites this paper
• Iron-refractory iron deficiency anemia: new molecular mechanisms.

  2009cites this paper
• Treatment with erythropoiesis stimulating agents

  2009cites this paper
• Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.

  2009cites this paper
• Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients.

  2009cites this paper
• Anemia management in oncology and hematology.

  2009cites this paper
• TOPIC HIGHLIGHT

  2009cites this paper
• Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.

  2009cites this paper
• Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease

  2009cites this paper
• Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment‐related anaemia: the need for predictors and indicators of effectiveness has not abated

  2008cites this paper
• Prediction of response to rhEPO in the anemia of cancer

  2008cites this paper
• Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines

  2008cites this paper
• Einsatz von Erythropoese-stimulierenden Proteinen bei anämischen Patienten mit malignen Erkrankungen

  2008cites this paper
• [Erythropoietin--use in hematologic oncology and radiotherapy].

  2008cites this paper
• Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level

  2008cites this paper
• Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option

  2007cites this paper
• Risks and benefits of erythropoiesis-stimulating agents in cancer management.

  2007cites this paper
• Erythropoietin and iron-restricted erythropoiesis.

  2007cites this paper
• Congestive heart failure-related anemia and a role for erythropoietin.

  2007cites this paper
• Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

  2007cites this paper
• Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma

  2007influential citation
• Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

  2007cites this paper
• Biological response modifiers in cancer.

  2006cites this paper
• Epoetin beta in oncology: examining the current evidence.

  2006cites this paper
• Cancer-related anemia and recombinant human erythropoietin—an updated overview

  2006cites this paper
• Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

  2006cites this paper
• The diagnostic plot

  2006cites this paper
• Einfluss des Hämoglobinwertes auf Prognose und Lebensqualität beim Bronchialkarzinom

  2005cites this paper
• Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

  2005cites this paper
• Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.

  2005cites this paper
• Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

  2005cites this paper
• Pre-treatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients*

  2005cites this paper
• Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.

  2005cites this paper
• Anaemia in Cancer Patients

  2005cites this paper
• Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update

  2005cites this paper
• Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?

  2005cites this paper
• Recombinant human erythropoietin in oncology: current status and further developments.

  2005cites this paper
• [Use of human recombinant erythropoietin in children with cancer].

  2005cites this paper
• [The effect of haemoglobin levels on prognosis and quality of life of patients with bronchial carcinoma].

  2005cites this paper
• Anemia of chronic disease.

  2005cites this paper
• Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.

  2004cites this paper
• THE EFFECTS OF ACUTE INFECTION ON HEMATOLOGICAL PARAMETERS

  2004cites this paper
• Hematology in palliative medicine

  2004cites this paper
• Anemia in Cancer: Therapeutic Implications and Interventions

  2003cites this paper
• Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy

  2003cites this paper
• [Anemia associated with malignancy].

  2003cites this paper
• Therapie mit Erythropoetinen in der Onkologie

  2003cites this paper
• The implications of anemia in multiple myeloma.

  2003cites this paper
• Anemia no doente oncológico

  2003cites this paper
• The Efficacy of rHuEPO in Cancer‐Related Anaemia

  2003cites this paper
• Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients.

  2003cites this paper
• Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group

  2003cites this paper
• [Anemia and chemotherapy].

  2003cites this paper
• Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

  2002cites this paper
• Pathogenesis and treatment of anaemia of chronic disease.

  2002cites this paper
• [Iron, infection and anemia--a classical triad].

  2002cites this paper
• Anemia of hematologic malignancies: what are the treatment options?

  2002cites this paper
• Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.

  2002cites this paper
• Management Options for Cancer Therapy-Related Anaemia

  2002cites this paper
• Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum‐based chemotherapy

  2002cites this paper
• Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

  2002cites this paper
• Darbepoetin Alfa: A Novel Erythropoiesis-Stimulating Protein

  2002cites this paper
• Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

  2002cites this paper
• [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].

  2002cites this paper
• Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis

  2002cites this paper
• Pharmaceutical biotechnology

  2002cites this paper
• Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

  2002cites this paper
• Organizing the Biomedical Paper

  2002cites this paper
• The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia.

  2002cites this paper
• Biological basis of anemia.

  2001cites this paper
• Recombinant human erythropoietin in the treatment of head and neck tumour anaemia.

  2001cites this paper
• Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy

  2001influential citation
• Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients

  2001cites this paper
• Pharmacotherapy of anaemia in cancer patients

  2001cites this paper
• Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

  2001cites this paper
• The treatment of anemia in peritoneal dialysis patients.

  2001cites this paper
• Soluble transferrin receptor for the evaluation of erythropoiesis and iron status.

  2001cites this paper
• Erythropoietin use and abuse: When physiology and pharmacology collide.

  2001cites this paper
• Advances in the biology and therapeutic management of multiple myeloma

  2001cites this paper
• Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

  2001cites this paper
• Erythropoietin for the treatment of anemia associated with hematological malignancy

  2001cites this paper
• Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response

  2000cites this paper
• The blood in systemic disorders.

  2000cites this paper
• Factors and Predictors of Response with Epoetin Alfa for Chemotherapy-Related Anemia

  2000cites this paper
• Anaemia in cancer: pathophysiology and treatment.

  2000cites this paper
• Psychometric testing of fatigue instruments for use with cancer patients.

  2000cites this paper
• Erythropoietin acute reaction and haematological adaptations to short, intermittent hypobaric hypoxia

  2000cites this paper